Evaluating the utility of an immune checkpoint-related lncRNA signature for identifying the prognosis and immunotherapy response of lung adenocarcinoma
Abstract Lung adenocarcinoma (LUAD) is the most frequent subtype of lung cancer globally. However, the survival rate of lung adenocarcinoma patients remains low. Immune checkpoints and long noncoding RNAs are emerging as vital tools for predicting the immunotherapeutic response and outcomes of patie...
| Váldodahkkit: | , , , , , , , , |
|---|---|
| Materiálatiipa: | Artihkal |
| Giella: | English |
| Almmustuhtton: |
Nature Portfolio
2022-07-01
|
| Ráidu: | Scientific Reports |
| Liŋkkat: | https://doi.org/10.1038/s41598-022-16715-0 |